JMP Securities Reiterates Market Outperform on LAVA Therapeutics, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on LAVA Therapeutics (NASDAQ:LVTX) and maintained a $6 price target.
August 23, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating on LAVA Therapeutics and maintained a $6 price target, which could positively impact the stock.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of a Market Outperform rating indicates that the analyst believes the stock will perform better than the overall market in the near term. The maintained price target of $6 also suggests that the analyst sees potential for the stock's price to rise. This could lead to increased investor interest in LVTX, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100